The Latest Breaking News from Jade Biosciences

Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody into patient studies for IgA nephropathy. Chief Executive Officer Tom Frohlich said JADE101,

MarketBeat · Jun 2

2 Small-Cap Stocks With Big Potential to Buy Under $30

These under-$30 stocks are betting on innovative therapies that could unlock massive long-term value.

Barchart · May 1